Influence of Kidney Function Estimation Methods on Carboplatin Dosing and Clinical Outcomes
Annals of Pharmacotherapy · 2026
DOI: 10.1177/10600280261430829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2026. Verfasst von Omar El Khatib und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. Hauptthemen laut MEDLINE: Carboplatin, Antineoplastic Agents, Kidney Function Tests, Kidney. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
The use of the Calvert formula for carboplatin dosing is well established. However, controversy persists regarding the choice of kidney function estimation equations, with oncology and nephrology guidelines offering differing recommendations.
Objective
This study aimed to compare the actual carboplatin doses administered to patients with those estimated using various kidney function equations, and to assess whether these differences could influence clinical outcomes.
Methods
This retrospective chart review included adult patients who received at least 1 dose of carboplatin at our institution between May 2015 and March 2024. Carboplatin doses were estimated using the Calvert formula with different kidney function equations and compared with the actual doses administered.
Results
A total of 360 patients met the inclusion criteria, with a median age of 57 years (46-68), a median weight of 72 kg (61-84), and 248 (68.9%) were female. Significant inter-method variability was observed in the median estimated kidney function and corresponding median carboplatin dosing across equations. Cockcroft-Gault (C-G) using actual body weight (110 mL/min, 677 mg), C-G with adjusted body weight (94 mL/min, 602 mg), 2021 CKD-EPI (chronic kidney disease epidemiology collaboration) (100 mL/min/1.73 m², 649 mg), 2021 CKD-EPI BSAAdj (101 mL/min, 658 mg), and the Janowitz equation (83 mL/min, 577 mg), P < 0.001. Hematologic toxicity, including febrile neutropenia, was significantly more common in patients dosed using C-G equation with actual body weight compared with adjusted body weight, occurring in 14/20 (70%) versus 5/115 (4.3%), respectively ( P < 0.001). Conclusion and Relevance: Carboplatin dosing varies significantly depending on the kidney function estimation method used. There is an urgent need for standardized, interdisciplinary dosing guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
- Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
ORCID-Profile: Omar El Khatib, Sara Zekery-Saad, Emna Abidi, Osama Abu Tabar, Wasim S El Nekidy
Zitieren
APA
El Khatib, O., Zekery-Saad, S., Abidi, E., Abdelaziz, A., Abu Tabar, O., Ahmed, M., Farooq, A., & El Nekidy, W. S. (2026). Influence of Kidney Function Estimation Methods on Carboplatin Dosing and Clinical Outcomes. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261430829
Vancouver
El Khatib O, Zekery-Saad S, Abidi E, Abdelaziz A, Abu Tabar O, Ahmed M, et al. Influence of Kidney Function Estimation Methods on Carboplatin Dosing and Clinical Outcomes. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261430829
BibTeX
@article{ElKhatib2026,
author = {El Khatib, Omar and Zekery-Saad, Sara and Abidi, Emna and Abdelaziz, Ahmed and Abu Tabar, Osama and Ahmed, Mohammed and Farooq, Anum and El Nekidy, Wasim S},
title = {Influence of Kidney Function Estimation Methods on Carboplatin Dosing and Clinical Outcomes},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261430829}
}
EUVIMED